Friedenthal Financial Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Friedenthal Financial bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 13,322 shares of the biopharmaceutical company's stock, valued at approximately $763,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Handelsbanken Fonder AB increased its holdings in Halozyme Therapeutics by 76.9% in the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company's stock valued at $112,715,000 after buying an additional 856,200 shares during the last quarter. TD Asset Management Inc raised its position in shares of Halozyme Therapeutics by 28.1% during the 1st quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company's stock valued at $103,379,000 after acquiring an additional 557,350 shares in the last quarter. Boston Trust Walden Corp bought a new position in Halozyme Therapeutics during the second quarter worth $23,211,000. Swedbank AB bought a new position in Halozyme Therapeutics during the first quarter worth $13,927,000. Finally, Epoch Investment Partners Inc. boosted its holdings in Halozyme Therapeutics by 23.3% in the first quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company's stock worth $58,319,000 after purchasing an additional 270,579 shares during the period. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

HALO stock traded up $0.33 during trading on Friday, reaching $52.61. 901,442 shares of the company's stock were exchanged, compared to its average volume of 1,285,821. Halozyme Therapeutics, Inc. has a 1-year low of $32.83 and a 1-year high of $65.53. The firm has a market cap of $6.70 billion, a PE ratio of 21.74, a P/E/G ratio of 0.49 and a beta of 1.27. The company's fifty day moving average price is $58.69 and its 200-day moving average price is $51.14. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The business had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. During the same quarter in the prior year, the company posted $0.68 earnings per share. The company's quarterly revenue was up 4.7% compared to the same quarter last year. On average, research analysts expect that Halozyme Therapeutics, Inc. will post 3.71 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. The Goldman Sachs Group increased their target price on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a "neutral" rating in a report on Monday, July 22nd. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and increased their price objective for the stock from $58.00 to $62.00 in a research note on Monday, October 7th. Benchmark restated a "buy" rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. Morgan Stanley increased their price target on Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 7th. Finally, Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Friday. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $60.44.

Insider Buying and Selling

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 5,000 shares of the stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $53.93, for a total transaction of $269,650.00. Following the completion of the transaction, the chief financial officer now directly owns 15,480 shares of the company's stock, valued at approximately $834,836.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO Helen Torley sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $52.58, for a total value of $525,800.00. Following the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at $35,583,199.52. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Nicole Labrosse sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $53.93, for a total transaction of $269,650.00. Following the sale, the chief financial officer now owns 15,480 shares of the company's stock, valued at $834,836.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 104,881 shares of company stock valued at $5,990,684 over the last quarter. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.